Abrezekimab (UCB4144) is an anti-IL-13 agent that is in development as an anti-asthmatic agent. Peptide sequences submitted to the WHO for the INN abrezekimab, match sequences claimed in UCB Pharma patent US8691233, namely sequence IDs 35 and 27 of the preferred antibody named Ab652 in the patent submission [2
]. This biologic has been designed as a high-affinity antibody fragment that suitable for inhalation, to provide a more rapid onset of action at lower doses than subcutaneous systemic administration [1
]. Efficacy has been demonstrated in asthma.